Combination Antibiotic Treatment With Linezolid for Staphylococcus Aureus Bacteraemia: a Randomised Controlled Trial

What this Trial Is About

Staphylococcus aureus bloodstream infections (bacteraemia) are serious and deadly bacterial infections that affect many people each year, with high rates of death and complications despite existing antibiotic treatments. The study aims to find out if adding linezolid, an antibiotic that may reduce harmful bacterial toxins, to standard antibiotic therapy can improve outcomes for patients with these infections. This trial is a randomized, placebo-controlled study designed to test this approach. Participants will be randomly assigned to receive either linezolid tablets at a dose of 600 mg twice daily for 5 days along with their usual antibiotic treatment or placebo tablets given on the same schedule with standard care. This study period lasts for 5 days of additional treatment. The trial compares these two groups to evaluate the impact of linezolid added to standard treatment on infection outcomes. During the study, participants will be closely monitored from the first day of randomization until 90 days later. Researchers will assess a variety of outcomes including overall health status, mortality, infection clearance, hospital stay length, antibiotic use, mental and physical health, and any side effects or adverse reactions. These evaluations include clinical exams, laboratory tests, and monitoring for complications or new antibiotic resistance. Safety and effectiveness data will be collected throughout the follow-up period to understand how well the treatment works and its impact on patients' recovery.

Linezolid Plus Standard of Care